Sygnature Discovery is delighted to announce the appointment of Amira Modi as its new Chief Operating Officer (COO) and Board member.

Amira brings extensive experience from the life sciences industry, having held leadership roles at both IQVIA and GSK. In her most recent role as Global Head Go-to-market Technology Solutions at IQVIA, she successfully led the integration of acquisitions and spearheaded the development and commercialization of integrated products and solutions for the market.

In her new role, Amira will play a crucial part in supporting the development and execution of Sygnature Discovery’s strategic objectives, lead group operations and provide leadership of the North American business.

She will focus on driving strategic and operational efficiency and change across the group, as part of ongoing efforts to build a sustainable and scalable business. With her expertise in the life sciences sector and experience in scaling businesses and managing M&A integrations, Amira will be instrumental in enhancing Sygnature’s data capabilities to optimize business management as it continues to grow and evolve.

Commenting on her appointment Amira said: “I am delighted to join Sygnature Discovery at this pivotal time to build on its successes to date and drive the next phase of growth. I was attracted to the role by both its reputation for scientific excellence and its ability to provide high quality and tailored services to clients. I look forward to utilizing my experience in transforming and leading diverse teams to drive Sygnature’s vision of becoming the leading global drug discovery CRO.”

“We are thrilled to welcome Amira to Sygnature Discovery,” said Dr Simon Hirst, CEO of Sygnature Discovery. “Her leadership and vision will undoubtedly make a significant impact as we continue to push the boundaries of innovation in drug discovery.

“Amira’s strategic insight and proven ability to lead transformative initiatives have consistently driven growth in global organizations. The Board believes that her alignment with Sygnature Discovery’s commitment to excellence, collaboration, and innovation makes her an ideal fit for this role. Her track record of leading high-performing teams and crafting innovative go-to-market strategies is poised to further strengthen our company.”

About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and NFP organizations. Since 2011, Sygnature Discovery has delivered over 40 novel pre-clinical and 25 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.